NCT00940498 - Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2012

Conditions

Neoplasms

Interventions

DRUG

PF-05212384 (also known as PKI-587)

Intravenous dosing once weekly infusion

Trial Locations (9)

Memorial Sloan-Kettering Cancer Center, New York

Memorial Sloan-Kettering Cancer Center, New York

Mayo Clinic, Rochester

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Insitute, Boston

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville

Hospital General Vall D'Hebron, Barcelona

King's College London, London